Envestnet Asset Management Inc. Boosts Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Envestnet Asset Management Inc. lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,805 shares of the biopharmaceutical company’s stock after buying an additional 795 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Agios Pharmaceuticals were worth $815,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after acquiring an additional 85,339 shares during the period. Fisher Asset Management LLC grew its position in shares of Agios Pharmaceuticals by 12.3% during the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company’s stock valued at $31,567,000 after purchasing an additional 105,333 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Agios Pharmaceuticals by 27.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 499,134 shares of the biopharmaceutical company’s stock worth $16,402,000 after purchasing an additional 107,292 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,547 shares of the biopharmaceutical company’s stock worth $15,528,000 after buying an additional 6,927 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Agios Pharmaceuticals by 48.8% during the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company’s stock valued at $8,725,000 after buying an additional 87,089 shares during the period.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $30.10 on Friday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of 2.65 and a beta of 0.83. The business has a 50 day moving average of $29.81 and a 200 day moving average of $37.84. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on AGIO. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research report on Friday. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.